PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007
REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

GHENT, Belgium, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Ablynx (Euronext
Brussels:ABLX) today announced, in accordance with Article 14 of the Belgian
Law of 2 May 2007 regarding the publication of major shareholdings in issuers
whose securities are admitted to trading on a regulated market (the
"Transparency Law"), that it received a notification of shareholdings from
Gimv NV and Biotech Fonds Vlaanderen NV.

The above shareholders notified that they have dropped below the 5% threshold
and now hold 2,208,702 Ablynx shares, which represent 4.53% of the current
48,802,115 outstanding shares of Ablynx.

Gimv NV controls Adviesbeheer Gimv Life Sciences NV and Adviesbeheer Gimv Life
Sciences 2004 NV. Gimv NV (929,473 voting rights), Adviesbeheer Gimv Life
Sciences NV (0 voting rights), Adviesbeheer Gimv Life Sciences 2004 NV
(165,040 voting rights) and Biotech Fonds Vlaanderen NV (1,114,189 voting
rights) are acting in mutual agreement. The Flemish Region in Belgium is the
ultimate shareholder of Biotech Fonds Vlaanderen NV.

Full versions of all transparency notifications are available on the website
of Ablynx, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in the pipeline and six Nanobodies at clinical
development stage. Ablynx has on-going research collaborations and significant
partnerships with major pharmaceutical companies including AbbVie, Boehringer
Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered
in Ghent, Belgium.

More information can be found on www.ablynx.com.

press release in pdf format: http://hugin.info/137912/R/1732864/579842.pdf

CONTACT: For more information, please contact
         Ablynx:
         Dr Edwin Moses
         Chairman and CEO
         t:   +32 (0)9 262 00 07
         m: +44 (0)7771 954 193 /
         +32 (0)473 39 50 68
         e:  edwin.moses@ablynx.com
        
         Marieke Vermeersch
         Associate Director Investor Relations
         t:   +32 (0)9 262 00 82
         m: +32 (0)479 49 06 03
         e:  marieke.vermeersch@ablynx.com
         Follow us on Twitter @AblynxABLX
        
         Ablynx media relations Consilium Strategic Communications:
         Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
         t:   +44 207 920 2345
         e:  ablynx@consilium-comms.com
 
Press spacebar to pause and continue. Press esc to stop.